BAC BV (Leiden, The Netherlands) and GE Healthcare (Wisconsin, USA) have announced receipt of the ‘Collaboration of the Decade’ award at the BioProcess International Awards 2012.
BAC BV (Leiden, The Netherlands) and GE Healthcare (Wisconsin, USA) have announced receipt of the ‘Collaboration of the Decade’ award at the BioProcess International Awards 2012. The award has been given in recognition of the collaboration between the two companies to develop innovative purification media for the production of novel biopharmaceuticals. With the increasing demand for biopharmaceuticals (resultant of an ageing population, rising obesity and global vaccine development), the demand for purification methods of higher efficiency has increased the importance of this collaboration since its formation.
The collaboration was formed in 2006, and the two companies have worked closely together to improve the efficiency of biopharmaceutical purification, specifically for use in the manufacture of antibodies, coagulation factors, biosimilars and gene therapy vectors.
Laurens Sierkstra, CEO of BAC, said: “We are delighted to see our joint efforts to enable the development of the latest biotherapeutics recognized by those in the industry. Our on-going collaboration with GE Healthcare has been highly productive and responsive to the needs of end-users.” Commenting on the award, Dr Nigel Darby, Vice President of BioTechnologies, GE Healthcare Life Sciences, added, “Collaborations between companies with complementary technologies and expertise are vital in making the advances that will help us tackle global challenges such as the increasing burden of disease and cost of healthcare. With global demand for cost-effective biotherapeutics set to rise, collaborations like ours that deliver innovative supporting technologies will play an increasingly significant role.”
For more information please visit:
ref=http://www.bacbv.com >www.bacbv.com
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.